{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:46:40Z","timestamp":1790419600472,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.coi.2017.07.006","type":"journal-article","created":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T09:45:25Z","timestamp":1501839925000},"page":"9-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["Pathophysiology and immunological profile of myasthenia gravis and its subgroups"],"prefix":"10.1016","volume":"49","author":[{"given":"Fredrik","family":"Romi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils Erik","family":"Gilhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2017.07.006_bib0005","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2017.07.006_bib0010","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis\u2014autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.coi.2017.07.006_sbref0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1212\/WNL.0b013e3181ad53c2","article-title":"Seropositive myasthenia gravis; a nationwide epidemiologic study","volume":"73","author":"Heldal","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.coi.2017.07.006_bib0020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"key":"10.1016\/j.coi.2017.07.006_bib0025","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.coi.2017.07.006_bib0030","first-page":"474512","article-title":"Thymoma in myasthenia gravis: from diagnosis to treatment","volume":"2011","author":"Romi","year":"2011","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.coi.2017.07.006_bib0035","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000329373","article-title":"Heat-shock proteins in clinical neurology","volume":"66","author":"Romi","year":"2011","journal-title":"Eur Neurol"},{"key":"10.1016\/j.coi.2017.07.006_sbref0040","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.expneurol.2015.02.010","article-title":"Thymoma related myasthenia gravis in humans and potential animal models","volume":"270","author":"Marx","year":"2015","journal-title":"Exp Neurol"},{"key":"10.1016\/j.coi.2017.07.006_bib0045","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.autrev.2015.09.005","article-title":"Thymoma associated with autoimmune diseases: 85 cases and literature review","volume":"15","author":"Bernard","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2017.07.006_bib0050","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3810\/pgm.2000.04.1003","article-title":"How to handle myasthenic crisis: essential steps in patient care","volume":"107","author":"Bedlack","year":"2000","journal-title":"Postgrad Med"},{"key":"10.1016\/j.coi.2017.07.006_bib0055","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s004150050059","article-title":"Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients","volume":"244","author":"Beekman","year":"1997","journal-title":"J Neurol"},{"key":"10.1016\/j.coi.2017.07.006_bib0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1196\/annals.1405.021","article-title":"Autoimmunizing mechanisms in thymoma and thymus","volume":"1132","author":"Willcox","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.coi.2017.07.006_bib0065","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s004150050604","article-title":"Muscle autoantibodies in subgroups of myasthenia gravis patients","volume":"247","author":"Romi","year":"2000","journal-title":"J Neurol"},{"key":"10.1016\/j.coi.2017.07.006_bib0070","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1196\/annals.1254.059","article-title":"Three forms of immune myasthenia","volume":"998","author":"Agius","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.coi.2017.07.006_bib0075","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0165-5728(95)00106-C","article-title":"Thymomas express epitopes shared by the ryanodine receptor","volume":"62","author":"Mygland","year":"1995","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.coi.2017.07.006_sbref0080","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.4049\/jimmunol.1601415","article-title":"Dysregulation of B cell repertoire formation in myasthenia gravis patients revealed through deep sequencing","volume":"198","author":"Vander Heiden","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2017.07.006_bib0085","doi-asserted-by":"crossref","first-page":"39716","DOI":"10.1038\/srep39716","article-title":"Profile of upregulated inflammatory proteins in sera of myasthenia gravis patients","volume":"7","author":"Molin","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2017.07.006_bib0090","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.coi.2017.07.006_sbref0095","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis","volume":"72","author":"Rodr\u00edguez Cruz","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.coi.2017.07.006_bib0100","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase, and low-density lipoprotein receptor-related protein 4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmune Rev"},{"key":"10.1016\/j.coi.2017.07.006_bib0105","doi-asserted-by":"crossref","first-page":"e108327","DOI":"10.1371\/journal.pone.0108327","article-title":"Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients","volume":"9","author":"Kordas","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coi.2017.07.006_sbref0110","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1523\/JNEUROSCI.3381-14.2015","article-title":"MuSK frizzled-like domain is critical for mammalian neuromuscular junction formation and maintenance","volume":"35","author":"Mess\u00e9ant","year":"2015","journal-title":"J Neurosci"},{"key":"10.1016\/j.coi.2017.07.006_sbref0115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jneuroim.2015.04.015","article-title":"MuSK autoantibodies in myasthenia gravis detected by cell-based assay: a multinational study","volume":"284","author":"Tsonis","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.coi.2017.07.006_bib0120","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1749-6632.2012.06808.x","article-title":"Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis","volume":"1275","author":"Plomp","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.coi.2017.07.006_bib0125","doi-asserted-by":"crossref","first-page":"13892","DOI":"10.1523\/JNEUROSCI.1733-14.2014","article-title":"LRP4 is critical for neuromuscular junction maintenance","volume":"34","author":"Barik","year":"2014","journal-title":"J Neurosci"},{"key":"10.1016\/j.coi.2017.07.006_bib0130","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.mod.2012.09.004","article-title":"The neuromuscular junction: selective remodeling of synaptic regulators at the nerve\/muscle interface","volume":"130","author":"Witzemann","year":"2013","journal-title":"Mech Dev"},{"key":"10.1016\/j.coi.2017.07.006_bib0135","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/WNL.0000000000000478","article-title":"Anti-agrin autoantibodies in myasthenia gravis","volume":"82","author":"Gasperi","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.coi.2017.07.006_sbref0140","doi-asserted-by":"crossref","first-page":"e91816","DOI":"10.1371\/journal.pone.0091816","article-title":"Autoantibodies to agrin in myasthenia gravis","volume":"9","author":"Zhang","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coi.2017.07.006_sbref0145","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2017.07.006_bib0150","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR and MuSK-antibody negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.coi.2017.07.006_bib0155","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.brainres.2007.08.035","article-title":"A role for LRP4 in neuronal cell viability is related to apoE-binding","volume":"1177","author":"Lu","year":"2007","journal-title":"Brain Res"},{"key":"10.1016\/j.coi.2017.07.006_bib0160","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/archneurol.2009.229","article-title":"Autoimmune targets of heart and skeletal muscles in myasthenia gravis","volume":"66","author":"Suzuki","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.coi.2017.07.006_bib0165","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00415-011-6344-y","article-title":"Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis","volume":"259","author":"Romi","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.coi.2017.07.006_bib0170","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000334862","article-title":"Serum levels of matrix metalloproteinases: implications in clinical neurology","volume":"67","author":"Romi","year":"2012","journal-title":"Eur Neurol"},{"key":"10.1016\/j.coi.2017.07.006_bib0175","first-page":"3629","article-title":"Titin force is enhanced in actively stretched skeletal muscle","volume":"217","author":"Powers","year":"2014","journal-title":"J Exp Biol"},{"key":"10.1016\/j.coi.2017.07.006_bib0180","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/ane.12271","article-title":"Anti-titin antibody in early and late onset myasthenia gravis","volume":"130","author":"Szczudlik","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.coi.2017.07.006_bib0185","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archneur.62.3.442","article-title":"Striational antibodies in myasthenia gravis; reactivity and possible clinical significance","volume":"62","author":"Romi","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.coi.2017.07.006_sbref0190","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jns.2014.12.015","article-title":"Collagen Q: a potential target for autoantibodies in myasthenia gravis","volume":"348","author":"Zoltowska Katarzyna","year":"2015","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.coi.2017.07.006_bib0195","doi-asserted-by":"crossref","first-page":"13928","DOI":"10.1038\/srep13928","article-title":"Collagen Q and anti-MuSK autoantibody competitively suppress agrin\/LRP4\/MuSK signaling","volume":"5","author":"Otsuka","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2017.07.006_bib0200","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jneuroim.2016.07.001","article-title":"Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patients","volume":"298","author":"Hong","year":"2016","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.coi.2017.07.006_bib0205","doi-asserted-by":"crossref","first-page":"e114060","DOI":"10.1371\/journal.pone.0114060","article-title":"Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development","volume":"9","author":"Heldal","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coi.2017.07.006_bib0210","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis; clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.coi.2017.07.006_bib0215","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coi.2017.07.006_bib0220","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/ene.12359","article-title":"EFNS\/ENS guidelines for the treatment of ocular myasthenia gravis","volume":"21","author":"Kerty","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.coi.2017.07.006_bib0225","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2353\/ajpath.2007.070240","article-title":"Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status","volume":"171","author":"Leite","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.coi.2017.07.006_bib0230","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun Rev"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791517300523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791517300523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:43:20Z","timestamp":1760604200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791517300523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":46,"alternative-id":["S0952791517300523"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2017.07.006","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathophysiology and immunological profile of myasthenia gravis and its subgroups","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2017.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}